Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Multi-Institutional Evaluation of Interrater Agreement of Variant Classification Based on the 2017 Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer.

Sirohi D, Schmidt RL, Aisner DL, Behdad A, Betz BL, Brown N, Coleman JF, Corless CL, Deftereos G, Ewalt MD, Fernandes H, Hsiao SJ, Mansukhani MM, Murray SS, Niu N, Ritterhouse LL, Suarez CJ, Tafe LJ, Thorson JA, Segal JP, Furtado LV.

J Mol Diagn. 2019 Dec 16. pii: S1525-1578(19)30435-0. doi: 10.1016/j.jmoldx.2019.10.010. [Epub ahead of print]

PMID:
31837433
2.

Non-Small Cell Lung Cancer as a Precision Oncology Paradigm: Emerging Targets and Tumor Mutational Burden (TMB).

Tafe LJ.

Adv Anat Pathol. 2020 Jan;27(1):3-10. doi: 10.1097/PAP.0000000000000244.

PMID:
31567128
3.

An Unusual Hybrid Salivary Gland Tumor: Molecular Analysis Informs the Potential Pathogenesis of This Rare Neoplasm.

Zhou Y, Martinez Duarte E, Eleff DJ, Tafe LJ, Leibowitz JM, Kerr DA.

Case Rep Pathol. 2019 Mar 28;2019:2713234. doi: 10.1155/2019/2713234. eCollection 2019.

4.

Pathologic Features and Clinical Implications of Breast Cancer With HER2 Intratumoral Genetic Heterogeneity.

Muller KE, Marotti JD, Tafe LJ.

Am J Clin Pathol. 2019 Jun 5;152(1):7-16. doi: 10.1093/ajcp/aqz010.

PMID:
30892594
5.

Pathologist-level classification of histologic patterns on resected lung adenocarcinoma slides with deep neural networks.

Wei JW, Tafe LJ, Linnik YA, Vaickus LJ, Tomita N, Hassanpour S.

Sci Rep. 2019 Mar 4;9(1):3358. doi: 10.1038/s41598-019-40041-7.

6.

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.

Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C.

J Immunother Cancer. 2019 Feb 1;7(1):27. doi: 10.1186/s40425-019-0506-3.

7.

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.

Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz-Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C.

J Immunother Cancer. 2019 Jan 24;7(1):18. doi: 10.1186/s40425-018-0489-5.

8.

A Syngeneic Mouse Model of Epithelial Ovarian Cancer Port Site Metastases.

Wilkinson-Ryan I, Pham MM, Sergent P, Tafe LJ, Berwin BL.

Transl Oncol. 2019 Jan;12(1):62-68. doi: 10.1016/j.tranon.2018.08.020. Epub 2018 Sep 27.

9.

Answer to September 2018 Photo Quiz.

Giurgea LT, Dillon JL, Tafe LJ, Zuckerman RA.

J Clin Microbiol. 2018 Aug 27;56(9). pii: e02147-16. doi: 10.1128/JCM.02147-16. Print 2018 Sep. No abstract available.

10.

Photo Quiz: An Immunosuppressed Acute Lymphoblastic Leukemia Patient with Fever and Lung Nodules.

Giurgea LT, Dillon JL, Tafe LJ, Zuckerman RA.

J Clin Microbiol. 2018 Aug 27;56(9). pii: e02146-16. doi: 10.1128/JCM.02146-16. Print 2018 Sep. No abstract available.

11.

Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations.

Linos K, Tafe LJ.

Histopathology. 2018 Dec;73(6):963-968. doi: 10.1111/his.13707. Epub 2018 Oct 16.

PMID:
30003571
12.

Computational immune profiling in lung adenocarcinoma reveals reproducible prognostic associations with implications for immunotherapy.

Varn FS, Tafe LJ, Amos CI, Cheng C.

Oncoimmunology. 2018 Mar 15;7(6):e1431084. doi: 10.1080/2162402X.2018.1431084. eCollection 2018.

13.

The Undergraduate Training in Genomics (UTRIG) Initiative: early & active training for physicians in the genomic medicine era.

Wilcox RL, Adem PV, Afshinnekoo E, Atkinson JB, Burke LW, Cheung H, Dasgupta S, DeLaGarza J, Joseph L, LeGallo R, Lew M, Lockwood CM, Meiss A, Norman J, Markwood P, Rizvi H, Shane-Carson KP, Sobel ME, Suarez E, Tafe LJ, Wang J, Haspel RL.

Per Med. 2018 May 1;15(3):199-208. doi: 10.2217/pme-2017-0077. Epub 2018 May 30.

14.

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.

Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL, Omilian A, Bshara W, Zibelman M, Ghatalia P, Dragnev K, Shirai K, Madden KG, Tafe LJ, Shah N, Kasuganti D, de la Cruz-Merino L, Araujo I, Saenger Y, Bogardus M, Villalona-Calero M, Diaz Z, Day R, Eisenberg M, Anderson SM, Puzanov I, Galluzzi L, Gardner M, Ernstoff MS.

J Immunother Cancer. 2018 May 9;6(1):32. doi: 10.1186/s40425-018-0344-8.

15.

Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations.

Toth LN, de Abreu FB, Tafe LJ.

Hum Pathol. 2018 Aug;78:138-143. doi: 10.1016/j.humpath.2018.04.014. Epub 2018 May 1.

PMID:
29723602
16.

Somatic polymerase epsilon mutations as another route leading to loss of DNA MMR protein expression in endometrial carcinoma-reply.

Tafe LJ.

Hum Pathol. 2018 Jun;76:170. doi: 10.1016/j.humpath.2018.01.029. Epub 2018 Apr 6. No abstract available.

PMID:
29630911
17.

Identifying Associations between Somatic Mutations and Clinicopathologic Findings in Lung Cancer Pathology Reports.

Kumar N, Tafe LJ, Higgins JH, Peterson JD, de Abreu FB, Deharvengt SJ, Tsongalis GJ, Amos CI, Hassanpour S.

Methods Inf Med. 2018 Feb;57(1):63-73. doi: 10.3414/ME17-01-0039. Epub 2018 Apr 5.

PMID:
29621832
18.
19.

A case of a primary lung cancer comprised of adenocarcinoma and atypical carcinoid tumor with both components harboring BRAF p.V600E mutation.

Olofson AM, Tafe LJ.

Exp Mol Pathol. 2018 Feb;104(1):26-28. doi: 10.1016/j.yexmp.2017.12.004. Epub 2017 Dec 14.

PMID:
29248665
20.

Evaluating melanocytic lesions with single nucleotide polymorphism (SNP) chromosomal microarray.

Hedayat AA, Linos K, Jung HS, Tafe LJ, Yan S, LeBlanc RE, Lefferts JA.

Exp Mol Pathol. 2017 Dec;103(3):279-287. doi: 10.1016/j.yexmp.2017.11.005. Epub 2017 Nov 21.

PMID:
29169801
21.

Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.

Dillon JL, Gonzalez JL, DeMars L, Bloch KJ, Tafe LJ.

Hum Pathol. 2017 Dec;70:121-128. doi: 10.1016/j.humpath.2017.10.022. Epub 2017 Oct 28.

PMID:
29107668
22.

P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site.

Marotti JD, Muller KE, Tafe LJ, Demidenko E, Miller TW.

Int J Breast Cancer. 2017;2017:4537532. doi: 10.1155/2017/4537532. Epub 2017 Jun 15.

23.

Intranodal meningothelial proliferation in a patient with Cowden syndrome: a case report.

Olofson A, Marotti J, Tafe LJ, Linos K.

Hum Pathol. 2017 Aug;66:183-187. doi: 10.1016/j.humpath.2017.03.002. Epub 2017 Mar 14.

PMID:
28315423
24.

Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets.

Tafe LJ.

Virchows Arch. 2017 Aug;471(2):155-164. doi: 10.1007/s00428-017-2101-7. Epub 2017 Mar 10. Review.

PMID:
28280929
25.

Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer.

Mustachio LM, Lu Y, Tafe LJ, Memoli V, Rodriguez-Canales J, Mino B, Villalobos PA, Wistuba I, Katayama H, Hanash SM, Roszik J, Kawakami M, Cho KJ, Hancock JF, Chinyengetere F, Hu S, Liu X, Freemantle SJ, Dmitrovsky E.

Mol Cancer Res. 2017 Jul;15(7):905-914. doi: 10.1158/1541-7786.MCR-16-0369. Epub 2017 Feb 27.

26.

Utility of the Roche Cobas 4800 for detection of high-risk human papillomavirus in formalin-fixed paraffin-embedded oropharyngeal squamous cell carcinoma.

Pettus JR, Wilson TL, Steinmetz HB, Lefferts JA, Tafe LJ.

Exp Mol Pathol. 2017 Feb;102(1):47-49. doi: 10.1016/j.yexmp.2016.12.004. Epub 2016 Dec 7.

PMID:
27939577
27.

Improving Adequacy of Small Biopsy and Fine-Needle Aspiration Specimens for Molecular Testing by Next-Generation Sequencing in Patients With Lung Cancer: A Quality Improvement Study at Dartmouth-Hitchcock Medical Center.

Padmanabhan V, Steinmetz HB, Rizzo EJ, Erskine AJ, Fairbank TL, de Abreu FB, Tsongalis GJ, Tafe LJ.

Arch Pathol Lab Med. 2017 Mar;141(3):402-409. doi: 10.5858/arpa.2016-0096-OA. Epub 2016 Oct 20.

PMID:
27763790
28.

Clinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes.

Tafe LJ, Pierce KJ, Peterson JD, de Abreu F, Memoli VA, Black CC, Pettus JR, Marotti JD, Gutmann EJ, Liu X, Shirai K, Dragnev KH, Amos CI, Tsongalis GJ.

Neoplasia. 2016 Sep;18(9):577-83. doi: 10.1016/j.neo.2016.07.010.

29.

Highly accurate molecular genetic testing for HFE hereditary hemochromatosis: results from 10 years of blinded proficiency surveys by the College of American Pathologists.

Press RD, Eickelberg G, McDonald TJ, Halley J, Long T, Tafe LJ, Weck KE.

Genet Med. 2016 Dec;18(12):1206-1213. doi: 10.1038/gim.2016.34. Epub 2016 Apr 28.

PMID:
27124787
30.

Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.

Muller KE, Marotti JD, de Abreu FB, Peterson JD, Miller TW, Chamberlin MD, Tsongalis GJ, Tafe LJ.

Exp Mol Pathol. 2016 Jun;100(3):421-5. doi: 10.1016/j.yexmp.2016.04.002. Epub 2016 Apr 16.

PMID:
27095739
31.

Proliferative lesion of anogenital mammary-like glands in the setting of Cowden syndrome: case report and review of the literature.

Hedayat AA, Pettus JR, Marotti JD, Tafe LJ, Holubar SD, Lisovsky M.

J Cutan Pathol. 2016 Aug;43(8):707-10. doi: 10.1111/cup.12721. Epub 2016 May 9. Review.

PMID:
27090873
32.

The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma.

Biernacka A, Tsongalis PD, Peterson JD, de Abreu FB, Black CC, Gutmann EJ, Liu X, Tafe LJ, Amos CI, Tsongalis GJ.

Cancer Genet. 2016 May;209(5):195-8. doi: 10.1016/j.cancergen.2016.03.001. Epub 2016 Mar 18.

33.

The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells.

Whipple CA, Boni A, Fisher JL, Hampton TH, Tsongalis GJ, Mellinger DL, Yan S, Tafe LJ, Brinckerhoff CE, Turk MJ, Mullins DW, Fadul CE, Ernstoff MS.

Melanoma Res. 2016 Jun;26(3):223-35. doi: 10.1097/CMR.0000000000000244.

PMID:
26974965
34.

An analysis of human papillomavirus testing and endocervical component on pap tests: A pilot study using the Roche Cobas(®) assay.

Pierce KJ, Currens HS, Tafe LJ, Tsongalis GJ, Padmanabhan V.

Diagn Cytopathol. 2016 Apr;44(4):280-2. doi: 10.1002/dc.23436. Epub 2016 Jan 23.

PMID:
26801205
35.

Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms: High Variant Concordance and Identification of Mutually Exclusive RAS Driver Mutations and MYC Amplification.

Tafe LJ, Muller KE, Ananda G, Mitchell T, Spotlow V, Patterson SE, Tsongalis GJ, Mockus SM.

Am J Pathol. 2016 Mar;186(3):671-7. doi: 10.1016/j.ajpath.2015.11.008. Epub 2016 Jan 18.

36.

Emerging Bladder Cancer Biomarkers and Targets of Therapy.

Netto GJ, Tafe LJ.

Urol Clin North Am. 2016 Feb;43(1):63-76. doi: 10.1016/j.ucl.2015.08.006. Review.

PMID:
26614029
37.

Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.

Hembrough T, Liao WL, Hartley CP, Ma PC, Velcheti V, Lanigan C, Thyparambil S, An E, Monga M, Krizman D, Burrows J, Tafe LJ.

Clin Chem. 2016 Jan;62(1):252-61. doi: 10.1373/clinchem.2015.245860. Epub 2015 Nov 19.

38.

Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.

Tafe LJ, Gorlov IP, de Abreu FB, Lefferts JA, Liu X, Pettus JR, Marotti JD, Bloch KJ, Memoli VA, Suriawinata AA, Dragnev KH, Fadul CE, Schwartz GN, Morgan CR, Holderness BM, Peterson JD, Tsongalis GJ, Miller TW, Chamberlin MD.

Oncologist. 2015 Sep;20(9):1011-8. doi: 10.1634/theoncologist.2015-0097. Epub 2015 Jul 23.

39.
40.

Targeted Next-Generation Sequencing for Hereditary Cancer Syndromes: A Focus on Lynch Syndrome and Associated Endometrial Cancer.

Tafe LJ.

J Mol Diagn. 2015 Sep;17(5):472-82. doi: 10.1016/j.jmoldx.2015.06.001. Epub 2015 Jul 8. Review.

41.

Nontender Parotid Mass in a Young Asian Man.

Ran C, Tafe LJ, Paydarfar JA.

JAMA Otolaryngol Head Neck Surg. 2015 Aug;141(8):763-4. doi: 10.1001/jamaoto.2015.0956. No abstract available.

PMID:
26042618
42.

A 78-year-old woman with brain metastases.

Tafe LJ, Tsongalis GJ.

Clin Chem. 2015 Apr;61(4):584-6. doi: 10.1373/clinchem.2014.229864. No abstract available.

43.

CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110.

Hu S, Danilov AV, Godek K, Orr B, Tafe LJ, Rodriguez-Canales J, Behrens C, Mino B, Moran CA, Memoli VA, Mustachio LM, Galimberti F, Ravi S, DeCastro A, Lu Y, Sekula D, Andrew AS, Wistuba II, Freemantle S, Compton DA, Dmitrovsky E.

Cancer Res. 2015 May 15;75(10):2029-38. doi: 10.1158/0008-5472.CAN-14-1494. Epub 2015 Mar 25.

44.

Small cell neuroendocrine carcinomas of the lung do not harbor high-risk human papillomavirus.

Hartley CP, Steinmetz HB, Memoli VA, Tafe LJ.

Hum Pathol. 2015 Apr;46(4):577-82. doi: 10.1016/j.humpath.2014.12.012. Epub 2015 Jan 9.

PMID:
25661244
45.

Regulatory T cells are not a strong predictor of survival for patients with glioblastoma.

Thomas AA, Fisher JL, Rahme GJ, Hampton TH, Baron U, Olek S, Schwachula T, Rhodes CH, Gui J, Tafe LJ, Tsongalis GJ, Lefferts JA, Wishart H, Kleen J, Miller M, Whipple CA, de Abreu FB, Ernstoff MS, Fadul CE.

Neuro Oncol. 2015 Jun;17(6):801-9. doi: 10.1093/neuonc/nou363. Epub 2015 Jan 24.

46.

Rapid fluorescence in situ hybridisation (FISH) for HER2 (ERBB2) assessment in breast and gastro-oesophageal cancer.

Tafe LJ, Steinmetz HB, Allen SF, Dokus BJ, Tsongalis GJ.

J Clin Pathol. 2015 Apr;68(4):306-8. doi: 10.1136/jclinpath-2014-202787. Epub 2015 Jan 9.

PMID:
25576545
47.

Benign phyllodes tumor of the breast recurring as a malignant phyllodes tumor and spindle cell metaplastic carcinoma.

Muller KE, Tafe LJ, de Abreu FB, Peterson JD, Wells WA, Barth RJ, Marotti JD.

Hum Pathol. 2015 Feb;46(2):327-33. doi: 10.1016/j.humpath.2014.10.014. Epub 2014 Nov 4.

PMID:
25476122
48.

Ovarian strumal carcinoid producing peptide YY associated with severe constipation: a case report and review of the literature.

Muller KE, Tafe LJ, Gonzalez JL, West LA, Schned AR.

Int J Gynecol Pathol. 2015 Jan;34(1):30-5. doi: 10.1097/PGP.0000000000000117. Review.

PMID:
25473750
49.

Molecular testing for the BRCA1 and BRCA2 Ashkenazi Jewish founder mutations: a report on the College of American Pathologists proficiency testing surveys.

Tafe LJ, Datto MB, Palomaki GE, Lacbawan FL; CAP/ACMG Biochemical and Molecular Genetics Resource Committee.

Genet Med. 2015 Jan;17(1):58-62. doi: 10.1038/gim.2014.77. Epub 2014 Jun 19.

PMID:
24946157
50.

Automated processing of fluorescence in-situ hybridization slides for HER2 testing in breast and gastro-esophageal carcinomas.

Tafe LJ, Allen SF, Steinmetz HB, Dokus BA, Cook LJ, Marotti JD, Tsongalis GJ.

Exp Mol Pathol. 2014 Aug;97(1):116-9. doi: 10.1016/j.yexmp.2014.06.003. Epub 2014 Jun 11.

PMID:
24927872

Supplemental Content

Support Center